author: Donna Trussell - Cancer and the Color Wars: Pink? Teal? Purple?

free full access: Sept 2010 Pegylated liposomal doxorubicin in the management of ovarian cancer

"This review aims at summarizing the available evidence and the new perspectives for the clinical role of PLD in the management of patients with epithelial ovarian cancer."

(U.S.) S. 1674: Improving Access to Clinical Trials Act of 2010 (GovTrack.us)

Text:
Summary
Status:

Occurred: Introduced Sep 15, 2009
Occurred: Referred to Committee View Committee Assignments
Occurred: Passed Senate Aug 5, 2010
Occurred: Passed House Sep 23, 2010
Not Yet Occurred: Signed by President ...
Having passed in identical form in both the House and Senate, this bill now awaits the signature of the President before becoming law. [Last Updated: Sep 29, 2010 9:33PM]
Last Action:
Sep 24, 2010: Presented to President.

Related:

See the Related Legislation page for other bills related to this one and a list of subject terms that have been applied to this bill. Sometimes the text of one bill or resolution is incorporated into another, and in those cases the original bill or resolution, as it would appear here, would seem to be abandoned.
Votes:

Aug 5, 2010: This bill passed in the Senate by Unanimous Consent. A record of each senator’s position was not kept.
Sep 23, 2010: This bill passed in the House of Representatives by voice vote. A record of each representative’s position was not kept.

free full access: Integrating Supportive and Palliative Care in the Trajectory of Cancer: Establishing Goals and Models of Care — JCO

"......One of the key barriers to early referral is the misunderstanding that palliative care is only provided at the end of life once patients have exhausted all cancer treatment options. Some oncologists have expressed the concern that a referral to palliative care would destroy a patient's hope. It is important to recognize that patients do not need to choose between cancer treatments and supportive/palliative care. Rather, they can take advantage of the expertise of both the oncology and the palliative care teams in optimizing quantity and quality of life under a simultaneous care model......"